Senti Biosciences Announces New Employment Inducement Grants

Barchart · 5d ago

SOUTH SAN FRANCISCO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that on June 3, 2025 Senti Bio’s Board of Directors granted to eight new employees stock options to purchase an aggregate of 102,500 shares of the Company’s common stock with a per share exercise price of $3.03. These awards were made under the Company’s Amended and Restated 2022 Inducement Equity Plan (the “Plan”).

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.